Editorial: Covid-19 therapies in patients with hematologic malignancies

Editorial: Covid-19 therapies in patients with hematologic malignancies

Bibliographic Details
Main Authors:	Andrea Visentin, Massimo Gentile
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Oncology
Subjects:	hematologic malignancies COVID tixagevimab/cilgavimab vaccine rituximab
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1382268/full

Similar Items

Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response
by: Krischan Braitsch, et al.
Published: (2024-08-01)

Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study
by: Hovav Azuly, et al.
Published: (2024-12-01)

Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19
by: Nicolina Capoluongo, et al.
Published: (2023-10-01)

Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.
by: Giovanni Manfredi Assanto ,, et al.
Published: (2023-10-01)

Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
by: Andrea Lombardi, et al.
Published: (2023-05-01)

Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study
by: Mohammed Kamal Nassar, et al.
Published: (2023-12-01)

The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
by: Shaymaa Glhoom, et al.
Published: (2024-01-01)

Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era
by: Alessandra Vergori, et al.
Published: (2024-07-01)

Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis
by: Luke B. Elias, et al.
Published: (2023-12-01)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
by: Daniele Focosi, et al.
Published: (2022-09-01)

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
by: F. D. Richard Hobbs, et al.
Published: (2024-02-01)

Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study
by: Dimitrios Basoulis, et al.
Published: (2024-08-01)

Cilgavimab and tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4/5 variants—a prospective cohort study (RESCUE-TX)Research in context
by: Roman Reindl-Schwaighofer, et al.
Published: (2024-11-01)

Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study
by: Jianhua You, et al.
Published: (2024-10-01)

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
by: Myron J. Levin, et al.
Published: (2024-05-01)

Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
by: Anna Gidari, et al.
Published: (2024-02-01)

Prolonged COVID-19 Infection in a Patient with Complete Remission from Follicular Lymphoma with Hyperosmolar Hyperglycemic Syndrome
by: Takuya Omura, et al.
Published: (2023-11-01)

Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results
by: T. V. Beketova, et al.
Published: (2024-11-01)

Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
by: T. V. Beketova, et al.
Published: (2023-04-01)

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
by: Gustavo H. Kijak, et al.
Published: (2023-11-01)

Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
by: Karolina Akinosoglou, et al.
Published: (2022-12-01)

Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis
by: Saad Alhumaid, et al.
Published: (2022-12-01)

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
by: Dejan Jakimovski, et al.
Published: (2023-02-01)

Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study
by: Jassada Buaboonnam, et al.
Published: (2024-12-01)

COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis
by: Saartje Demolder, et al.
Published: (2024-01-01)

An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab
by: Tali Shafat, et al.
Published: (2024-02-01)

COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices
by: Karolina Akinosoglou, et al.
Published: (2023-03-01)

Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
by: Jessica S. Little, et al.
Published: (2021-12-01)

Effectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review
by: Carolina Garcia Vidal, et al.
Published: (2025-02-01)

Adverse Hematological Effects of COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies
by: Armand N. Yazdani, et al.
Published: (2023-03-01)

Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis
by: Saeed Khorramnia, et al.
Published: (2024-06-01)

Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future
by: David A. Van Eijndhoven, et al.
Published: (2025-02-01)

Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients
by: Cesare Ernesto Maria Gruber, et al.
Published: (2023-10-01)

Using Tocilizumab in Hematologic Malignant Patients with Severe COVID-19 Infection – Case Series Report
by: Fu C, et al.
Published: (2024-01-01)

Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study
by: Odit Gutwein, et al.
Published: (2023-11-01)

Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19
by: Monika Maria Biernat, et al.
Published: (2021-03-01)

COVID-19 in Hematologic Malignancies: Big Challenges
by: Yongxian Hu, et al.
Published: (2020-10-01)

Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy
by: M. V. Zhuravleva, et al.
Published: (2023-07-01)

A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies
by: Carolyn Owen, et al.
Published: (2022-05-01)

Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience
by: Andrea Cona, et al.
Published: (2024-07-01)